|
Form
20-F ☒
|
Form
40-F ☐
|
|
Exhibit
Number
|
Description
|
99.1
|
04
October 2024 - “Holding(s) in
Company”
|
GB00BMX86B70
|
HALEON PLC
|
UK
|
An acquisition or disposal of voting rights
|
Pfizer Inc.
|
New York
|
United States of America
|
Name
|
City
of registered office
|
Country
of registered office
|
State
Street Nominees Limited
|
London
|
United
Kingdom
|
Guaranty Nominees
Limited
|
London
|
United
Kingdom
|
03-Oct-2024
|
03-Oct-2024
|
|
%
of voting rights attached to shares (total of 8.A)
|
%
of voting rights through financial instruments (total of 8.B 1 +
8.B 2)
|
Total
of both in % (8.A + 8.B)
|
Total
number of voting rights held in issuer
|
Resulting situation
on the date on which threshold was crossed or reached
|
15.040000
|
0.000000
|
15.040000
|
1361709764
|
Position of
previous notification (if applicable)
|
22.580000
|
0.000000
|
22.580000
|
|
Class/Type of shares ISIN code(if possible)
|
Number of direct voting rights (DTR5.1)
|
Number of indirect voting rights (DTR5.2.1)
|
% of direct voting rights (DTR5.1)
|
% of indirect voting rights (DTR5.2.1)
|
Ordinary Shares
GB00BMX86B70
|
|
967251860
|
|
10.680000
|
Restricted
ADSs
|
|
394457904
|
|
4.360000
|
Sub
Total 8.A
|
1361709764
|
15.040000%
|
Type of financial instrument
|
Expiration date
|
Exercise/conversion period
|
Number of voting rights that may be acquired if the instrument is
exercised/converted
|
% of voting rights
|
|
|
|
|
|
Sub
Total 8.B1
|
|
|
|
Type of financial instrument
|
Expiration date
|
Exercise/conversion period
|
Physical or cash settlement
|
Number of voting rights
|
% of voting rights
|
|
|
|
|
|
|
Sub
Total 8.B2
|
|
|
|
1. Person subject to the notification obligation is not controlled
by any natural person or legal entity and does not control any
other undertaking(s) holding directly or indirectly an interest in
the (underlying) issuer.
|
Ultimate controlling person
|
Name of controlled undertaking
|
% of voting rights if it equals or is higher than the notifiable
threshold
|
% of voting rights through financial instruments if it equals or is
higher than the notifiable threshold
|
Total of both if it equals or is higher than the notifiable
threshold
|
|
|
|
|
|
|
|
|
This notification relates to the sale by Pfizer Inc. ("Pfizer") of
a portion of its interest in Haleon plc ("Haleon").Pfizer sold
640,000,000 Haleon ordinary shares ("Ordinary Shares") pursuant to
a secondary offering announced on 30 September 2024. In connection
with the offering, and in addition to the 640,000,000 Ordinary
Shares in the offering, Pfizer sold 60,526,315 Ordinary Shares to
Haleon in an off-market sale in accordance with the terms of a
share purchase deed between Haleon and Pfizer that was previously
approved by Haleon's shareholders.These calculations are based on
Haleon's issued voting share capital of 9,053,360,882 ordinary
shares with voting rights, as communicated by Haleon in their
announcement on total voting rights and capital dated 3 October
2024.Pfizer holds its ordinary shares in Haleon through (i) State
Street Nominees Limited, and (ii) Guaranty Nominees Limited (in
respect of its American depositary shares representing Ordinary
Shares), which hold the legal title to those shares on Pfizer's
behalf.
|
03-Oct-2024
|
New York
|
|
|
HALEON PLC
(Registrant)
|
|
Date: October 04, 2024
|
By:
|
/s/
Amanda Mellor
|
|
|
|
Name:
|
Amanda
Mellor
|
|
|
Title:
|
Company
Secretary
|